Wyeth Pharmaceuticals has decided to extend its research collaboration with Trubion Pharmaceuticals for an additional year. For these additional research services, Trubion will receive approximately $3.2 million.
The original agreement between the two companies was inked in December 2005 for the development and worldwide commercialization of TRU-015, Trubion’s lead product that is currently in Phase II development for the treatment of rheumatoid arthritis, and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20.
Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting